AP2013007159A0 - Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase - Google Patents
Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinaseInfo
- Publication number
- AP2013007159A0 AP2013007159A0 AP2013007159A AP2013007159A AP2013007159A0 AP 2013007159 A0 AP2013007159 A0 AP 2013007159A0 AP 2013007159 A AP2013007159 A AP 2013007159A AP 2013007159 A AP2013007159 A AP 2013007159A AP 2013007159 A0 AP2013007159 A0 AP 2013007159A0
- Authority
- AP
- ARIPO
- Prior art keywords
- tropomyosin
- pyrrolo
- inhibitors
- pyrimidine derivatives
- related kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471758P | 2011-04-05 | 2011-04-05 | |
| PCT/IB2012/051363 WO2012137089A1 (en) | 2011-04-05 | 2012-03-22 | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2013007159A0 true AP2013007159A0 (en) | 2013-10-31 |
Family
ID=45937493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2013007159A AP2013007159A0 (en) | 2011-04-05 | 2012-03-22 | Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8846698B2 (he) |
| EP (1) | EP2694509B1 (he) |
| JP (1) | JP5595616B2 (he) |
| KR (1) | KR20130133905A (he) |
| CN (1) | CN103534257A (he) |
| AP (1) | AP2013007159A0 (he) |
| AR (1) | AR085852A1 (he) |
| AU (1) | AU2012238369A1 (he) |
| BR (1) | BR112013025792A2 (he) |
| CA (1) | CA2832291C (he) |
| CL (1) | CL2013002821A1 (he) |
| CO (1) | CO6801740A2 (he) |
| CR (1) | CR20130470A (he) |
| CU (1) | CU20130129A7 (he) |
| DO (1) | DOP2013000221A (he) |
| EA (1) | EA201391239A1 (he) |
| EC (1) | ECSP13013009A (he) |
| ES (1) | ES2581848T3 (he) |
| GE (1) | GEP20156417B (he) |
| GT (1) | GT201300236A (he) |
| IL (1) | IL228590A0 (he) |
| MA (1) | MA35024B1 (he) |
| MX (1) | MX2013011612A (he) |
| NI (1) | NI201300103A (he) |
| PE (1) | PE20141050A1 (he) |
| SG (1) | SG193513A1 (he) |
| TN (1) | TN2013000394A1 (he) |
| TW (1) | TWI443101B (he) |
| UA (1) | UA108926C2 (he) |
| UY (1) | UY34004A (he) |
| WO (1) | WO2012137089A1 (he) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9193723B2 (en) * | 2012-05-11 | 2015-11-24 | Abbvie Inc. | NAMPT inhibitors |
| CA2885247A1 (en) * | 2012-10-04 | 2014-04-10 | Pfizer Limited | Tropomyosin-related kinase inhibitors |
| US9163021B2 (en) | 2012-10-04 | 2015-10-20 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
| JP2015531394A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤 |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| NZ710079A (en) | 2013-01-15 | 2020-01-31 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| US9447026B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| JP2016169161A (ja) * | 2013-07-19 | 2016-09-23 | 大日本住友製薬株式会社 | 新規イミダゾピリジン化合物 |
| AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
| TWI731317B (zh) | 2013-12-10 | 2021-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑 |
| WO2015089170A1 (en) | 2013-12-12 | 2015-06-18 | Kalyra Pharmaceuticals, Inc. | Bicyclic alkyl compounds and synthesis |
| JP2016540811A (ja) | 2013-12-20 | 2016-12-28 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤 |
| CA2937074A1 (en) * | 2014-01-24 | 2015-07-30 | Abbvie Inc. | Furo-3-carboxamide derivatives and methods of use |
| JP6197125B2 (ja) | 2014-02-05 | 2017-09-13 | ブイエム オンコロジー リミテッド ライアビリティ カンパニー | 化合物の組成物およびその使用 |
| CN113336653A (zh) | 2014-03-07 | 2021-09-03 | 里科瑞尔姆Ip控股有限责任公司 | 螺桨烷衍生物及合成 |
| WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| EP3140298A1 (en) * | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
| CN103992319B (zh) * | 2014-05-27 | 2015-09-16 | 天津市斯芬克司药物研发有限公司 | 一种吡啶羧酸类化合物的制备方法 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
| WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
| CA2961605C (en) * | 2014-09-17 | 2023-01-10 | Kalyra Pharmaceuticals, Inc. | Bicyclic compounds |
| EP3233057A2 (en) | 2014-12-18 | 2017-10-25 | Genzyme Corporation | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors |
| WO2016104434A1 (ja) * | 2014-12-24 | 2016-06-30 | 武田薬品工業株式会社 | 複素環化合物 |
| CN105837574B (zh) * | 2015-02-02 | 2018-03-02 | 四川大学 | N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途 |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| US10550124B2 (en) | 2015-08-13 | 2020-02-04 | San Diego State University Foundation | Atropisomerism for increased kinase inhibitor selectivity |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| JP6873980B2 (ja) | 2015-09-14 | 2021-05-19 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CN109415366B (zh) * | 2016-06-23 | 2022-02-22 | 豪夫迈·罗氏有限公司 | [1,2,3]三唑并[4,5-d]嘧啶衍生物 |
| CN107011347B (zh) * | 2017-04-18 | 2019-01-18 | 华东师范大学 | 一种4-氯-7H-吡咯并[2,3-d]嘧啶的合成方法 |
| NZ759268A (en) | 2017-05-15 | 2022-07-01 | Recurium Ip Holdings Llc | Bicyclo[1.1.1]pentyl compounds as analgesics |
| EP3641776B1 (en) | 2017-06-23 | 2023-10-18 | San Diego State University Research Foundation | Atropisomerism for enhanced kinase inhibitor selectivity |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| TW202003519A (zh) * | 2018-03-28 | 2020-01-16 | 日商武田藥品工業股份有限公司 | 雜環化合物及其用途 |
| CN109053575A (zh) * | 2018-08-24 | 2018-12-21 | 遵义医学院 | 3-环丙基-1-甲基-1h-吡唑-4-甲醛的制备工艺 |
| WO2020084389A1 (en) * | 2018-10-23 | 2020-04-30 | Lupin Limited | Ribociclib intermediate and process for preparation thereof |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AR122141A1 (es) | 2020-05-28 | 2022-08-17 | Lilly Co Eli | Inhibidor de trka |
| WO2022268080A1 (zh) * | 2021-06-21 | 2022-12-29 | 河南迈英诺医药科技有限公司 | Trk激酶抑制剂化合物及其用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| TW438796B (en) | 1996-05-15 | 2001-06-07 | Hoffmann La Roche | 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| IL131582A0 (en) * | 1997-03-19 | 2001-01-28 | Basf Ag | Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤 |
| GB0218168D0 (en) * | 2002-08-06 | 2002-09-11 | Astrazeneca Ab | Compounds |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| US20070185079A1 (en) | 2004-01-07 | 2007-08-09 | Astrazeneca Ab | Therapeutic agents I |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| CA2566160C (en) * | 2004-05-27 | 2011-01-18 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
| BRPI0610066A2 (pt) * | 2005-05-17 | 2010-05-25 | Plexxikon Inc | compostos que modulam atividade de c-kit e c-fms e usos para estes |
| WO2007042545A1 (en) | 2005-10-14 | 2007-04-19 | Neurosearch A/S | Imidazole derivatives and their use for modulating the gaba-a receptor complex |
| GB0526044D0 (en) | 2005-12-21 | 2006-02-01 | Syngenta Ltd | Novel herbicides |
| RU2323058C1 (ru) | 2006-07-12 | 2008-04-27 | ООО Научно-внедренческий центр "Машины и оборудование для энергетики" | Способ формирования наружной резьбы на концевом участке трубной заготовки |
| PT2076508E (pt) | 2006-10-18 | 2011-03-07 | Pfizer Prod Inc | Compostos de ureia de éter biarílico |
| AU2007336811A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8357711B2 (en) | 2007-03-23 | 2013-01-22 | Pfizer Limited | Heterocyclic sulfonamides as inhibitors of ion channels |
| KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
| EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009152087A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor |
| JP5767965B2 (ja) | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症 |
| BRPI1006128A2 (pt) | 2009-01-12 | 2016-11-01 | Cagen Inc | derivados de sulfonamida |
| KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
-
2012
- 2012-03-22 BR BR112013025792A patent/BR112013025792A2/pt not_active IP Right Cessation
- 2012-03-22 AU AU2012238369A patent/AU2012238369A1/en not_active Abandoned
- 2012-03-22 CA CA2832291A patent/CA2832291C/en not_active Expired - Fee Related
- 2012-03-22 EA EA201391239A patent/EA201391239A1/ru unknown
- 2012-03-22 SG SG2013070032A patent/SG193513A1/en unknown
- 2012-03-22 KR KR1020137029237A patent/KR20130133905A/ko active IP Right Grant
- 2012-03-22 EP EP12713362.7A patent/EP2694509B1/en active Active
- 2012-03-22 JP JP2014503236A patent/JP5595616B2/ja not_active Expired - Fee Related
- 2012-03-22 GE GEAP201213253A patent/GEP20156417B/en unknown
- 2012-03-22 AP AP2013007159A patent/AP2013007159A0/xx unknown
- 2012-03-22 MA MA36302A patent/MA35024B1/fr unknown
- 2012-03-22 UA UAA201311548A patent/UA108926C2/ru unknown
- 2012-03-22 PE PE2013002178A patent/PE20141050A1/es not_active Application Discontinuation
- 2012-03-22 ES ES12713362.7T patent/ES2581848T3/es active Active
- 2012-03-22 MX MX2013011612A patent/MX2013011612A/es unknown
- 2012-03-22 WO PCT/IB2012/051363 patent/WO2012137089A1/en active Application Filing
- 2012-03-22 CN CN201280022159.2A patent/CN103534257A/zh active Pending
- 2012-03-30 UY UY0001034004A patent/UY34004A/es not_active Application Discontinuation
- 2012-04-02 TW TW101111719A patent/TWI443101B/zh not_active IP Right Cessation
- 2012-04-04 AR ARP120101171A patent/AR085852A1/es unknown
- 2012-04-04 US US13/439,131 patent/US8846698B2/en not_active Expired - Fee Related
-
2013
- 2013-09-17 CR CR20130470A patent/CR20130470A/es unknown
- 2013-09-27 TN TNP2013000394A patent/TN2013000394A1/fr unknown
- 2013-09-29 IL IL228590A patent/IL228590A0/he unknown
- 2013-09-30 CU CU2013000129A patent/CU20130129A7/es unknown
- 2013-09-30 CL CL2013002821A patent/CL2013002821A1/es unknown
- 2013-10-03 NI NI201300103A patent/NI201300103A/es unknown
- 2013-10-04 DO DO2013000221A patent/DOP2013000221A/es unknown
- 2013-10-04 CO CO13236624A patent/CO6801740A2/es active IP Right Grant
- 2013-10-04 GT GT201300236A patent/GT201300236A/es unknown
- 2013-11-05 EC ECSP13013009 patent/ECSP13013009A/es unknown
-
2014
- 2014-08-26 US US14/468,614 patent/US20140364415A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2013007159A0 (en) | Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase | |
| HUS2200003I1 (hu) | Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai | |
| HRP20171724T1 (hr) | Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze | |
| HK1192248A1 (en) | Pyrazolo[4,3-d]pyrimidines useful as kinase inhibitors [43-d] | |
| HK1222659A1 (zh) | 吡咯並 嘧啶衍生物，它們的製備方法和它們作爲激酶抑制劑的用途 | |
| ZA201306545B (en) | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of betasecretase (bace) | |
| EP2608669A4 (en) | NEW PYRAZOLO- [1,5-A-] PYRIMIDINE DERIVATIVES AS ANTI-MTOR HEMMER | |
| HK1189229A1 (zh) | 三環吡咯並衍生物、它們的製備方法和它們作為激酶抑制劑的應用 | |
| IL217414A0 (en) | SUBSTITUTED PYRAZOLO[1, 5-a] PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | |
| HK1189223A1 (zh) | 用作β分泌酶 抑制劑的 -二氫-吡咯並 吡嗪- -基胺衍生物 | |
| EP2661437A4 (en) | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO [2,3] PYRIMIDINE DERIVATIVES AS FAK / PYK2 INHIBITORS | |
| EP2525659A4 (en) | PYRAZOLO [1,5-A] PYRIMIDINES COMPOUNDS AS MTOR INHIBITORS | |
| EP2739627A4 (en) | 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2 | |
| HK1209740A1 (en) | Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use --[23-d] pi3k | |
| PL2694513T3 (pl) | Pochodne pirazolopirymidynowe | |
| SG10201408059QA (en) | 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases | |
| EP2523552A4 (en) | PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER |